The Global Pulmonary Arterial Hypertension (PAH) Treatment Market is set for steady growth, with an estimated market size of USD 5,811.5 million in 2023. According to industry forecasts, the market is projected to reach USD 7,224.4 million by 2033, reflecting a compound annual growth rate (CAGR) of 2.2% during the forecast period from 2023 to 2033.
Key Market Drivers
The growth of the pulmonary arterial hypertension treatment market is largely driven by the increasing prevalence of PAH, a progressive and life-threatening disease that affects the blood vessels in the lungs and the right side of the heart. The rising diagnosis rates, alongside the growing demand for effective treatments, are contributing to the market’s expansion.
In addition, significant advancements in drug therapies, including the development of novel medications and combination therapies, are expected to drive the market further. As healthcare providers continue to improve PAH diagnosis and treatment options, the market is anticipated to witness sustained demand for innovative therapies and management options.
Key Takeaways
- Market Value in 2023: USD 5,811.5 million
- Projected Market Value by 2033: USD 7,224.4 million
- CAGR: 2.2% from 2023 to 2033
- Growth Drivers: Increasing PAH prevalence, advancements in drug therapies, and growing awareness of the condition.
Regional Insights
- North America: The largest market share, driven by advanced healthcare infrastructure, high awareness, and access to cutting-edge treatment options.
- Europe: Steady growth with a strong focus on improving diagnosis and expanding access to newer therapeutic options.
- Asia-Pacific: Rapidly growing market, driven by increasing healthcare investments, rising awareness, and improving access to treatment in emerging economies such as China and India.
- Latin America & Middle East/Africa: Gradual adoption, with increasing healthcare access and rising focus on managing chronic diseases like PAH.
Key Insights
The increasing incidence of pulmonary arterial hypertension globally is a significant factor driving the demand for effective treatment options. PAH is a severe condition that can lead to heart failure if left untreated, necessitating ongoing advancements in therapeutic strategies.
Growth Drivers
Several factors are contributing to the growth of the PAH treatment market:
- Rising Prevalence of PAH: An increase in diagnosed cases of pulmonary arterial hypertension is prompting healthcare providers to seek effective treatments.
- Advancements in Treatment Options: Innovations in drug therapies and emerging treatment modalities are enhancing patient outcomes and expanding the market.
- Increased Awareness and Screening: Growing awareness about the disease and improved screening methods are leading to earlier diagnosis and treatment initiation.\
Competitive Landscape
Collaborations between manufacturers, end-users, and research institutions can lead to the development of innovative pulmonary arterial hypertension treatment-based solutions for emerging applications.
The key strategies chosen by large companies include several growth strategies such as technology development, expansion as well and mergers and acquisitions to surge market share, reach and revenue.
- In 2023, United Therapeutics Corporation announced the launch of its new PAH treatment, Tyvaso DPI (treprostinil). Tyvaso DPI is a dry powder inhaler formulation of treprostinil that is designed to improve the convenience and delivery of treprostinil treatment for PAH patients.
- In 2023, Verfora Pharmaceuticals announced the initiation of a Phase 3 clinical trial of its new PAH treatment, VER-205. VER-205 is a novel oral PAH treatment that is designed to improve the efficacy and tolerability of PAH treatment.
- In 2022, Bayer Pharmaceuticals announced the expansion of its clinical trial program for its PAH treatment, Adempas (riociguat). Bayer is conducting clinical trials to evaluate the use of Adempas in combination with other PAH treatments and to evaluate the use of Adempas in PAH patients with different comorbidities.
- In 2022, Eli Lilly and Company announced the acquisition of Akros Therapeutics, a company that is developing new PAH treatments. The acquisition gives Lilly access to Akros Therapeutics’ portfolio of PAH treatments, including its lead drug candidate, AKR-001.
Key Companies Profiled
- United Therapeutics Ltd.
- Bayer AG
- Actelion Ltd.
- Pfizer, Inc.
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Teva Pharmaceuticals Inc.
- Eli Lilly and Company
- Steady Med Ltd.
- Johnson & Johnson Services, Inc.
A Detailed Full Report
Segmentation Analysis of the Pulmonary Arterial Hypertension Treatment Market
Drug Type:
- Vasodilators
- Phosphodiesterase 5 (PDE 5) Inhibitors
- Endothelin Receptor Antagonists (ERA)
- Soluble Guanylate Cyclase (SGC) Stimulator
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia & Pacific
- East Asia
- The Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
